Success Metrics

Clinical Success Rate
85.4%

Based on 105 completed trials

Completion Rate
85%(105/123)
Active Trials
25(14%)
Results Posted
43%(45 trials)
Terminated
18(10%)

Phase Distribution

Ph phase_4
40
22%
Ph not_applicable
36
20%
Ph phase_3
29
16%
Ph phase_2
45
25%
Ph early_phase_1
7
4%
Ph phase_1
20
11%

Phase Distribution

27

Early Stage

45

Mid Stage

69

Late Stage

Phase Distribution177 total trials
Early Phase 1First-in-human
7(4.0%)
Phase 1Safety & dosage
20(11.3%)
Phase 2Efficacy & side effects
45(25.4%)
Phase 3Large-scale testing
29(16.4%)
Phase 4Post-market surveillance
40(22.6%)
N/ANon-phased studies
36(20.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.9%

105 of 133 finished

Non-Completion Rate

21.1%

28 ended early

Currently Active

25

trials recruiting

Total Trials

183

all time

Status Distribution
Active(27)
Completed(105)
Terminated(28)
Other(23)

Detailed Status

Completed105
unknown23
Recruiting20
Terminated18
Withdrawn10
Active, not recruiting5

Development Timeline

Analytics

Development Status

Total Trials
183
Active
25
Success Rate
85.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (4.0%)
Phase 120 (11.3%)
Phase 245 (25.4%)
Phase 329 (16.4%)
Phase 440 (22.6%)
N/A36 (20.3%)

Trials by Status

withdrawn105%
completed10557%
recruiting2011%
active_not_recruiting53%
not_yet_recruiting11%
enrolling_by_invitation11%
terminated1810%
unknown2313%

Recent Activity

Clinical Trials (183)

Showing 20 of 183 trialsScroll for more
NCT00097474Phase 2

Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag

Completed
NCT06136650Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Recruiting
NCT06136624Phase 3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Recruiting
NCT05836610Phase 4

Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates

Recruiting
NCT06104449Phase 1

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Completed
NCT00859781Phase 2

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Active Not Recruiting
NCT04924166Phase 2

PTSD Prevention Using Oral Hydrocortisone

Completed
NCT06136598Phase 1

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Completed
NCT06892197Phase 4

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

Recruiting
NCT06892210Phase 4

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Recruiting
NCT05435781Phase 4

Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency

Recruiting
NCT05292664Phase 1

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting
NCT06942039Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting
NCT05436535Phase 4

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Completed
NCT05160506Phase 2

Corticosteroids to Treat Pancreatitis

Recruiting
NCT03913559Phase 2

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Terminated
NCT06381661Phase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not Yet Recruiting
NCT03020030Phase 3

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active Not Recruiting
NCT02517489Phase 3

Community-Acquired Pneumonia : Evaluation of Corticosteroids

Completed
NCT05193396Phase 4

Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
183